Ionis Pharmaceuticals, Kastle Therapeutics deal

Kastle purchased from Ionis worldwide rights to develop and commercialize cholesterol drug Kynamro mipomersen. Ionis will receive $15 million up front plus $10 million to be paid in three years. The company is eligible for up to $70 million in sales milestones, plus low- to mid-teen royalties and a 10% common equity position in Kastle. ...